Evidence map›Paper›PMID 42534363›Full record

ArticleCase reports in medicine2026

Unusual Sequential Development of Multiple Sclerosis, Thymoma, Myasthenia, and Lymphoma in the Same Patient.

Josef Finsterer

Abstract read
In one paragraph

Article in Case reports in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Josef FinstererNeurology Neurophysiology Center, Vienna, Austria.ORCID https://orcid.org/0000-0003-2839-7305

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

No case has yet been described in which a patient developed multiple sclerosis (MS) followed by thymoma, myasthenia gravis (MG), and T-cell lymphoma. The patient is a 47-year-old woman who developed relapsing-remitting MS at the age of 31 and was treated with interferon-beta (IFN-β) for over seven years. She was then diagnosed with thymoma, which was treated with chemotherapy and surgery. One year later, she was diagnosed with MG, which was treated with steroids, pyridostigmine, and intravenous immunoglobulins. Due to an MS relapse at the age of 40, ocrelizumab was administered for 2.5 years, after which she developed T-cell lymphoma. As the lymphoma had responded only partially to chemotherapy, an autologous stem cell transplantation was performed. It remains unclear whether there was a causal link between the immunosuppressive MS treatment and the thymoma or lymphoma, whether these developed due to underlying immune dysregulation, individual predisposition, or the cumulative effect of prior oncological therapies, or whether this was merely a chance co-occurrence of rare diseases. The case shows that a single patient may sequentially develop MS, MG, thymoma, and T-cell lymphoma. Fundamental and comprehensive clinical studies are required to elucidate the underlying pathophysiology and to confirm or refute a possible causal link.

Indexed as

interferonlymphomamultiple sclerosismyastheniathymoma

Identifiers

PMID42534363
PMCPMC13420281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.